Close Menu
Money MechanicsMoney Mechanics
    What's Hot

    The SEC drops its four-year-old investigation into EV startup Faraday Future

    March 23, 2026

    Better Oil Stock: Chevron vs. Occidental Petroleum

    March 22, 2026

    1 Stock to Buy, 1 Stock to Sell This Week: Ondas, PDD

    March 22, 2026
    Facebook X (Twitter) Instagram
    Trending
    • The SEC drops its four-year-old investigation into EV startup Faraday Future
    • Better Oil Stock: Chevron vs. Occidental Petroleum
    • 1 Stock to Buy, 1 Stock to Sell This Week: Ondas, PDD
    • Ras Laffan attacks could reshape global LNG supply as outage timeline extends – Oil & Gas 360
    • Pershing Square IPO: Should You Buy the PSUS IPO?
    • How Long Will This Rally in Gold and Silver Take?
    • Today’s Homebuyers Save $150 a Month By Choosing an Adjustable-Rate Mortgage
    • After getting hit by multiple data breaches, I gave DeleteMe a try – here’s how it’s paid off
    Facebook X (Twitter) Instagram
    Money MechanicsMoney Mechanics
    • Home
    • Markets
      • Stocks
      • Crypto
      • Bonds
      • Commodities
    • Economy
      • Fed & Rates
      • Housing & Jobs
      • Inflation
    • Earnings
      • Banks
      • Energy
      • Healthcare
      • IPOs
      • Tech
    • Investing
      • ETFs
      • Long-Term
      • Options
    • Finance
      • Budgeting
      • Credit & Debt
      • Real Estate
      • Retirement
      • Taxes
    • Opinion
    • Guides
    • Tools
    • Resources
    Money MechanicsMoney Mechanics
    Home»Guides & How-To»Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism
    Guides & How-To

    Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism

    Money MechanicsBy Money MechanicsSeptember 5, 2025No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Key Takeaways

    • Kenvue’s stock slumped Friday after The Wall Street Journal reported federal officials plan to link use of one of its products, Tylenol, with autism.
    • Kenvue said it has “continuously evaluated” Tylenol and believes there is no link between its active ingredient, acetaminophen, and autism.
    • A number of other over-the-counter drugs contain acetaminophen, but their manufacturers’ stocks haven’t taken the same hit as Kenvue.

    Shares of Tylenol-maker Kenvue (KVUE) plunged over 9% Friday following a report that federal health officials may link use of the painkiller during pregnancy to autism.

    Health Secretary Robert F. Kennedy Jr. plans to announce a report saying the use of Tylenol during pregnancy may be one of several causes of autism, The Wall Street Journal reported Friday afternoon, citing people familiar with the matter. A spokesperson for the Department of Health and Human Services told Investopedia that it is “using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates,” and that until the final report is released, any claims about its contents should be treated as speculation.

    Kenvue said the active ingredient in Tylenol, acetaminophen, was studied for more than a decade by the U.S. Federal Drug Administration, which concluded research hasn’t supported a causal link between acetaminophen and autism.

    “Nothing is more important to us than the health and safety of the people who use our products,” Kenvue said in a statement. “We have continuously evaluated the science and continue to believe there is no causal link between acetaminophen use during pregnancy and autism.”

    RFK Jr., who has pledged to identify the cause of autism, has also previously voiced concerns about vaccines and other medical treatments deemed safe by the medical establishment.

    A number of other painkillers and congestion relievers available without prescriptions contain acetaminophen, including Benadryl, Sudafed, DayQuil, Excedrin, NyQuil, Robitussin and Vicks, according to BeMedWise, a patient safety and education group. Benadryl and Sudafed are sold by Kenvue in the U.S., according to Kenvue’s website.

    Shares of manufacturers for many of the other products with acetaminophen haven’t taken the same hit as Kenvue. Haleon (HLN), which sells Excedrin and Robitussin, was recently off by less than 1%, while shares of Procter & Gamble (PG), which sells Vicks, DayQuil and NyQuil, finished Friday’s session up less than 1%.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleKiplinger News Quiz, September 5, 2025
    Next Article Frontier GoWild! Pass Review 2025: Is the $299 All-You-Can-Fly Deal Worth It?
    Money Mechanics
    • Website

    Related Posts

    I’m Ready to Retire in Europe Now. My Wife Thinks It’s Too Risky. Who’s Right?

    March 22, 2026

    My First $1 Million: Information Tech Engineer, 54, Nashville

    March 21, 2026

    Ask the Tax Editor: Questions on Tax Changes for 2026

    March 20, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    The SEC drops its four-year-old investigation into EV startup Faraday Future

    March 23, 2026

    Better Oil Stock: Chevron vs. Occidental Petroleum

    March 22, 2026

    1 Stock to Buy, 1 Stock to Sell This Week: Ondas, PDD

    March 22, 2026

    Ras Laffan attacks could reshape global LNG supply as outage timeline extends – Oil & Gas 360

    March 22, 2026

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading

    At Money Mechanics, we believe money shouldn’t be confusing. It should be empowering. Whether you’re buried in debt, cautious about investing, or simply overwhelmed by financial jargon—we’re here to guide you every step of the way.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Links
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Resources
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To
    Get Informed

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading
    Copyright© 2025 TheMoneyMechanics All Rights Reserved.
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To

    Type above and press Enter to search. Press Esc to cancel.